Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Immunotherapy vs Observation in ESCC
NCT07067450Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Randomised, open-label trial of pembrolizumab, tislelizumab, sintilimab, camrelizumab and toripalimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Sichuan University. Primary endpoint: Disease-Free Survival at 2 years. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07067450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07067450.